Press Releases



 
Press Releases
  Date Title View
Feb 16, 2017
REDWOOD CITY, Calif., Feb. 16, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) announced today the presentation of results from four studies evaluating the clinical value and utility of its Oncotype DX® Genomic Prostate Score™ (GPS) in the management of early-stage prostate cancer. Collectively, these new data highlight the test...
PDF
Feb 14, 2017
REDWOOD CITY, Calif., Feb. 14, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2016. Total revenue was $327.9 million in the full year 2016, compared with $287.5 million in 2015, an increase of 14 percent. U.S. product revenue ...
PDF
Feb 7, 2017
REDWOOD CITY, Calif., Feb. 7, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, February 14 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2016 financial results.  The call and webcast will follow the release of the fourth quarter and y...
PDF
Jan 3, 2017
REDWOOD CITY, Calif., Jan. 3, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 9, 2017 at 11:00 a.m. Pacific Ti...
PDF
Dec 22, 2016
REDWOOD CITY, Calif., Dec. 22, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that based on unparalleled clinical evidence, the American Joint Committee on Cancer (AJCC) incorporated the Oncotype DX® test in its recently published Eighth Edition AJCC Cancer Staging Manual. Representing a rigorous, multi-disciplinary a...
PDF
Dec 9, 2016
REDWOOD CITY, Calif., Dec. 9, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple studies demonstrating the unparalleled value of the Oncotype DX® test in individualizing breast cancer treatment decisions for patients with various stages of the disease. Presentations included two overviews of prospect...
PDF
Nov 29, 2016
REDWOOD CITY, Calif., Nov. 29, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present seven Oncotype DX® studies at the 39th CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which is being held December 6-10, 2016. The study findings reinforce the Company's leadership in individualizing breast cance...
PDF
Nov 3, 2016
REDWOOD CITY, Calif., Nov. 3, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, chief operating officer and chief financial officer, will present at the Credit Suisse 25th Annual Healthcare Conference in Scottsdale, Arizona on Tuesday, November 8, 2016 at 3:30 p.m. Mountain Time. To access the live and...
PDF
Nov 1, 2016
REDWOOD CITY, Calif., Nov. 1, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended September 30, 2016. Total revenue was $82.3 million in the third quarter of 2016, compared with $73.6 million in the third quarter of 2015, an increase of 12 percent. U.S. ...
PDF
Nov 1, 2016
REDWOOD CITY, Calif., Nov. 1, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced topline results from a large clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™ (GPS). The study, performed in collaboration with a large integrated healthcare system, met its primary endpoint by demonstr...
PDF
1
...
NextLast